Analyst Stock Ratings: Tonix Pharmaceuticals Holding Corp. (TNXP), Newater Technology, Inc. (NEWA)

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) tinted loss of -2.13% (-0.04 points) to US$1.84. The volume of 0.18 Million shares climbed down over an trading activity of 797.63 Million shares. EPS ratio determined by looking at last 12 month figures is -28.85. Over the same time span, the stock marked US$51.1 as its best level and the lowest price reached was US$1.7. The corporation has a market cap of US$11.28 Million.

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)’s earnings per share has been growing at a 43.7 percent rate over the past 5 year when average revenue increase was noted as 0 percent. The return on equity ratio or ROE stands at -131.9 percent while most common profitability ratio return on investment (ROI) was 0 percent. The company’s institutional ownership is monitored at 12.3 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 0 percent gross margin.

Daily Analyst Recommendations

A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 0 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 2 think it is Hold. Recently, analysts have updated the overall rating to 2.5. 2 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.

Newater Technology, Inc. (NASDAQ:NEWA) is worth US$71.11 Million and has recently risen 2.52% to US$6.5. The latest exchange of 0.07 Million shares is below its average trading activity of 22.79 Million shares. The day began at US$0 but the price moved to US$0 at one point during the trading and finally capitulating to a session high of US$0. The stock tapped a 52-week high of US$29.69 while the mean 12-month price target for the shares is US$0.

Currently, the stock carries a price to earnings ratio of 6.98, a price to book ratio of 2.54, and a price to sales ratio of 1.59. For the past 5 years, the company’s revenue has grown 0%, while the company’s earnings per share has grown 0%. With an institutional ownership near 5.1%, it carries an earnings per share ratio of 0.93.